Sotorasib-Induced Bullous Pemphigoid in a Patient with Non-Small Cell Lung Cancer

Abstract

Gurpoonam Jatana, Hasan Salih, Rajan Chopra, Mohammed Al Abadie and John Forgi

Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disorder typically seen in the older adults, characterized by tense bullae and intense pruritus. Although BP can be idiopathic, medications are being increasingly recognized as their triggers. Sotorasib, is a KRAS G12C inhibitor approved for the non-small cell lung cancer (NSCLC) treatment; it can have associated dermatologic side effects; however, the reports of BP induced with this drug are almost non-existent. We present a unique case of Sotorasib-induced BP in a patient with advanced NSCLC, highlighting the importance of recognizing this potential cutaneous complication in the patients receiving novel targeted therapy [1].

PDF